Roche has received the US FDA’s approval for its human papillomavirus (HPV) self-collection solution with its cobas HPV test to detect cervical cancer at the earliest for the treatment
The HPV self-collection solution works by screening vaginal samples from the individuals which are sent to labs for analysis through Roche’s cobas molecular instrument to detect if the patient is HPV positive or not for further treatment
Additionally, Roche teamed up with the National Cancer Institute (NCI) for the Cervical Cancer “Last Mile” Initiative, facilitating the regulatory approval process
Ref: Roche | Image: Roche
Related News:- Roche to Highlight the P-III (OCARINA II) Trial Results of Ocrevus for Treating Progressive and Relapsing Multiple Sclerosis at AAN 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
